[Rituximab (antiCD20 monoclonal antibody) and molecular-biological negativity in the treatment of patients with follicular lymphoma--a way to a cure?--Editorial].
Trnený
M
M
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000276:immunology; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D050438:Genes, Immunoglobulin Heavy Chain / Q000235:genetics; D019254:Genes, bcl-2 / Q000235:genetics; D006801:Humans; D008224:Lymphoma, Follicular / Q000188:drug therapy* / Q000235:genetics; D011379:Prognosis; D012074:Remission Induction; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D000069283:Rituximab